Investigating a protein's role in lung blood vessel disease
Official title: Role of Endothelial Anoctamin-1 in Pulmonary Arterial Hypertension
Funded at Ocean State Research Institute, INC. · NIH-10449284 · Data updated 2026-11-12
This study is looking at how a protein called Anoctamin-1 affects the growth of certain cells in the lungs of people with pulmonary arterial hypertension (PAH), with the hope of finding new treatments that could help improve their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ocean State Research Institute, INC. NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project start | July 1, 2019 |
| Project end | June 30, 2025 |
| Funding year | 2022 |
| Award (this year) | $391,771 |
| NIH project number | 5R01HL148727-04 |
| Project ID | NIH-10449284 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension who are experiencing significant symptoms and have limited treatment options.
✕Less likely to help
Patients with other forms of pulmonary hypertension or those without significant endothelial dysfunction may not benefit from this research.
What this research studies
This research focuses on pulmonary arterial hypertension (PAH), a serious condition that affects blood vessels in the lungs. It aims to understand how a specific protein, Anoctamin-1, contributes to the abnormal growth and survival of endothelial cells in PAH. By exploring the mechanisms behind this protein's activity, the research seeks to identify new treatment strategies that could reduce harmful cell proliferation and promote cell death in these dysfunctional cells. Patients may benefit from potential therapies that target these processes to improve their condition.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reduce the severe vascular remodeling associated with pulmonary arterial hypertension.
How similar studies have gone: While the specific approach of targeting Anoctamin-1 in PAH is novel, similar strategies targeting dysfunctional endothelial cells have shown promise in other vascular diseases.
Where this research is happening
-
Ocean State Research Institute, INC.
Providence, United States Active
Researchers
- Principal investigator: Choudhary, Gaurav — Ocean State Research Institute, INC.
- Study coordinator: Choudhary, Gaurav
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.